<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-350 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-350</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-350</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-6.html">extraction-schema-6</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing Asian and non-Asian populations, and any proposed explanations for ethnic differences.</div>
                <p><strong>Paper ID:</strong> paper-164502a687f04effb4ac5dadbdd9d806fde4264c</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/164502a687f04effb4ac5dadbdd9d806fde4264c" target="_blank">Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.</a></p>
                <p><strong>Paper Venue:</strong> Journal of Clinical Oncology</p>
                <p><strong>Paper TL;DR:</strong> This study represents the first comprehensive and concurrent analysis of major recurrent oncogenic mutations found in a large cohort of lung adenocarcinomas from East Asian never-smokers and indicates that prospective mutation testing in these patients should successfully assign a targeted therapy in the majority of cases.</p>
                <p><strong>Cost:</strong> 0.009</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e350.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e350.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing Asian and non-Asian populations, and any proposed explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR_EastAsian_never-smokers_2010</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>EGFR mutation prevalence in East Asian (Chinese) never-smokers (Sun et al., 2010)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>This study reports a very high prevalence of EGFR kinase-domain mutations in resected lung adenocarcinomas from Chinese never-smokers: 78.8% overall, with the majority being exon 19 deletions or exon 21 L858R substitutions; mutations were mutually exclusive with other major drivers in most cases.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_ethnicity</strong></td>
                            <td>East Asian (Chinese)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_location</strong></td>
                            <td>Shanghai, China</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td>52</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>78.8% (41 of 52 tumors; 95% CI 0.6580 to 0.8792)</td>
                        </tr>
                        <tr>
                            <td><strong>specific_mutation_types</strong></td>
                            <td>Exon 19 deletions: 21 cases (~40.4% of total, 51.2% of EGFR-mutant cases); Exon 21 L858R: 18 cases (~34.6% of total, 43.9% of EGFR-mutant cases); one exon 20 insertion; one double mutation involving exon 18 (G719S) + exon 21 (L861Q); no T790M detected.</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_with_other_ethnicities</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>comparative_frequency_data</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status_correlation</strong></td>
                            <td>Study restricted to never-smokers; paper states EGFR mutations are enriched in never-smokers and that EGFR mutation likelihood decreases as pack-years increase (cited prior work).</td>
                        </tr>
                        <tr>
                            <td><strong>gender_correlation</strong></td>
                            <td>Higher prevalence in females in this cohort: 82.9% (34 of 41 female tumors) vs 63.6% (7 of 11) in males (values refer to proportion of tumors from each sex that harbored EGFR mutations).</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_genetic</strong></td>
                            <td>No specific genetic mechanism for ethnic differences is proposed in this paper; the paper notes differences in mutation spectra across populations (and cites other studies) but does not propose a causal hereditary mechanism.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_environmental</strong></td>
                            <td>No environmental explanation for ethnic differences is proposed in this paper beyond noting the correlation of smoking exposure with lower EGFR mutation frequency.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_lifestyle</strong></td>
                            <td>The paper highlights smoking history as correlated (EGFR mutations enriched in never-smokers; likelihood decreases with increasing pack-years) but does not propose other lifestyle explanations for ethnic differences.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_other</strong></td>
                            <td>The paper suggests that molecular subtype differences (different distributions of driver mutations such as lower KRAS and LKB1 mutation rates in East Asians) underlie population differences; also notes that concurrent mutations (eg, PIK3CA) or exon 20 insertions may affect therapeutic sensitivity. No formal hypothesis (e.g., detection bias or healthcare access) is advanced for ethnic differences.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_histology</strong></td>
                            <td>Adenocarcinoma (resected lung adenocarcinomas)</td>
                        </tr>
                        <tr>
                            <td><strong>response_to_egfr_inhibitors</strong></td>
                            <td>Paper cites published response rates: IPASS overall response to gefitinib 43%; response in EGFR-mutant patients 71.2%; WJTOG3405 reported ~62.1% in EGFR-mutant patients. For this cohort, after excluding predicted resistant genotypes (one exon 20 insertion and four with concurrent PIK3CA), authors estimate ~69% would be predicted sensitive and compute an expected true response rate â‰ˆ48% for the whole cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.', 'publication_date_yy_mm': '2010-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e350.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e350.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing Asian and non-Asian populations, and any proposed explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Ethnic_comparison_mentions</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Mentions of ethnic differences in EGFR/KRAS/LKB1 mutation prevalence (from literature cited in paper)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>The paper discusses and cites prior observations that EGFR mutations are enriched in East Asian (and never-smoker) patients, whereas KRAS and LKB1 mutations are more common in non-Asian/Caucasian patients; specific comparative data are cited from prior studies but not directly measured in this cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_ethnicity</strong></td>
                            <td>Asian (East Asian) versus non-Asian / Caucasian (mentioned in discussion and citations)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_location</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>Not directly quantified across ethnicities within this paper; the paper states EGFR mutations are enriched in East Asian patients and cites prior studies for cross-ethnic comparisons.</td>
                        </tr>
                        <tr>
                            <td><strong>specific_mutation_types</strong></td>
                            <td>Paper refers generally to common activating EGFR mutations (exon 19 deletions and exon 21 L858R) being enriched in East Asian/never-smoker populations; also notes exon 20 insertions associate with resistance.</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_with_other_ethnicities</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>comparative_frequency_data</strong></td>
                            <td>No numeric cross-ethnic frequencies provided in this paper itself; the paper references other studies reporting reversed KRAS/EGFR mutation rates in Taiwan and higher LKB1 mutation frequency in Caucasians than Asians (see cited references).</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status_correlation</strong></td>
                            <td>Paper emphasizes that ethnic associations are partly observed in never-smoker subgroups and that smoking (pack-years) reduces EGFR mutation likelihood.</td>
                        </tr>
                        <tr>
                            <td><strong>gender_correlation</strong></td>
                            <td>Paper and cited literature note female sex correlates with higher EGFR mutation frequency (observed in this cohort and prior reports).</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_genetic</strong></td>
                            <td>Paper does not propose detailed genetic mechanisms for ethnic differences, but cites studies showing population-specific mutation patterns (eg, LKB1 mutations more frequent in Caucasians).</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_environmental</strong></td>
                            <td>No explicit environmental causal hypotheses for ethnic differences are proposed in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_lifestyle</strong></td>
                            <td>Smoking behavior is discussed as affecting mutation prevalence; beyond smoking, no other lifestyle factors are proposed to explain ethnic differences.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_other</strong></td>
                            <td>Paper implies that differences in the distribution of molecular driver subsets (EGFR, KRAS, HER2, ALK, LKB1) between populations may explain observed ethnic differences in therapeutic responses and mutation prevalence; cites literature rather than proposing new mechanisms.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_histology</strong></td>
                            <td>Adenocarcinoma (context: comparisons discussed pertain mainly to adenocarcinoma subsets)</td>
                        </tr>
                        <tr>
                            <td><strong>response_to_egfr_inhibitors</strong></td>
                            <td>Paper cites that East Asian ethnicity and never-smoking status were associated with higher likelihood of responding to EGFR TKIs in retrospective studies, and references IPASS (East Asian trial) where EGFR mutation status predicted benefit from gefitinib.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.', 'publication_date_yy_mm': '2010-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma <em>(Rating: 2)</em></li>
                <li>Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications <em>(Rating: 2)</em></li>
                <li>Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients <em>(Rating: 2)</em></li>
                <li>EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy <em>(Rating: 1)</em></li>
                <li>Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>